Home / Stocks / NAGE

Niagen Bioscience (NAGE, Personal Care Products) Stock Valuation & Fair Value Quality business with a solid forward outlook

Niagen Bioscience (NAGE, Personal Care Products) trades at a blended P/E of 18.4, about 54% below its historical normal valuation, with a forward growth estimate of 20.7% and a PEG of 0.89. Priced at its historical normal P/E of 40.0 on the same blended earnings, the 2026-09-18 close of $2.99 corresponds to about $6.50 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
18.4
Normal P/E
40.0
PEG
0.89
Fwd growth
20.7%
Div yield
0.0%
RSI (14)
48.9
Neutral

The Street vs SeerForecast

Wall Street's mean price target for NAGE is $12.08 across 6 analysts, 302.8% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: quality business with a solid forward outlook. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been quality business with a solid forward outlook since 2026-07-31.

Blended P/E and rating by weekBlended P/E moved from 16.8 to 18.4 between 2026-07-31 and 2026-09-21, against a normal P/E of 40.0, with 0 rating changes over 18 recorded weeks.2026-07-31: P/E 16.8, Quality business with a solid forward outlook (recalculated)2026-08-03: P/E 17.2, Quality business with a solid forward outlook2026-08-07: P/E 17.2, Quality business with a solid forward outlook (recalculated)2026-08-10: P/E 18.4, Quality business with a solid forward outlook2026-08-14: P/E 18.4, Quality business with a solid forward outlook (recalculated)2026-08-17: P/E 18.0, Quality business with a solid forward outlook2026-08-21: P/E 18.0, Quality business with a solid forward outlook (recalculated)2026-08-24: P/E 19.3, Quality business with a solid forward outlook2026-08-27: P/E 19.3, Quality business with a solid forward outlook (recalculated)2026-08-28: P/E 19.3, Quality business with a solid forward outlook (recalculated)2026-08-30: P/E 19.3, Quality business with a solid forward outlook (recalculated)2026-08-31: P/E 19.9, Quality business with a solid forward outlook2026-09-05: P/E 19.9, Quality business with a solid forward outlook (recalculated)2026-09-07: P/E 19.3, Quality business with a solid forward outlook2026-09-12: P/E 19.3, Quality business with a solid forward outlook (recalculated)2026-09-14: P/E 18.6, Quality business with a solid forward outlook2026-09-19: P/E 18.6, Quality business with a solid forward outlook (recalculated)2026-09-21: P/E 18.4, Quality business with a solid forward outlook20.030.040.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 40.0
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 16.8-58%Quality business with a solid forward outlook
2026-08-31P/E 19.9-50%Quality business with a solid forward outlook
2026-09-21P/E 18.4-54%Quality business with a solid forward outlook ← now

Frequently asked questions

Is Niagen Bioscience stock overvalued?

At a blended P/E of 18.4 versus its historical normal P/E of 40.0, Niagen Bioscience trades about 54% below its typical valuation, with a PEG of 0.89 on 20.7% forward growth. tickerseer currently rates it quality business with a solid forward outlook.

What is Niagen Bioscience's fair value and PEG?

Niagen Bioscience trades at a blended P/E of 18.4 against a historical normal P/E of 40.0, a PEG of 0.89, and a forward growth estimate of 20.7%. Priced at its historical normal P/E of 40.0 on the same blended earnings, the 2026-09-18 close of $2.99 corresponds to about $6.50 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Niagen Bioscience changed?

tickerseer's rating has been quality business with a solid forward outlook since 2026-07-31.

What is the analyst price target for Niagen Bioscience?

The mean Wall Street price target for Niagen Bioscience is $12.08 across 6 analysts, 302.8% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Personal Care Products. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track NAGE free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.